Inogen, Inc. (INGN) Stock Competitors & Peer Comparison
See (INGN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INGN | $6.17 | +1.31% | 161.9M | -6.57 | -$0.91 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $89.94 | +3.42% | 151.5B | 24.37 | $3.57 | +2.80% |
| ISRG | $415.27 | +3.22% | 144.2B | 49.37 | $8.25 | N/A |
| SYK | $302.26 | +3.05% | 113.1B | 34.11 | $8.65 | +1.17% |
| MDT | $80.72 | +9.45% | 100.2B | 21.80 | $3.58 | +3.66% |
| BSX | $48.84 | +2.43% | 70.9B | 19.96 | $2.39 | N/A |
| BRKRP | $462.12 | +7.99% | 70.4B | N/A | N/A | +0.33% |
| EW | $87.09 | -0.65% | 49.5B | 46.51 | $1.85 | N/A |
| DXCM | $74.09 | +0.87% | 28.1B | 31.23 | $2.33 | N/A |
Stock Comparison
INGN vs BSX-PA Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, INGN is priced at $6.17, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, INGN's ROE is -0.13%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, INGN is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check BSX-PA's competition here
INGN vs ABT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ABT has a market cap of 151.5B. Regarding current trading prices, INGN is priced at $6.17, while ABT trades at $89.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ABT's P/E ratio is 24.37. In terms of profitability, INGN's ROE is -0.13%, compared to ABT's ROE of +0.12%. Regarding short-term risk, INGN is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ABT's competition here
INGN vs ISRG Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ISRG has a market cap of 144.2B. Regarding current trading prices, INGN is priced at $6.17, while ISRG trades at $415.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ISRG's P/E ratio is 49.37. In terms of profitability, INGN's ROE is -0.13%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, INGN is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ISRG's competition here
INGN vs SYK Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SYK has a market cap of 113.1B. Regarding current trading prices, INGN is priced at $6.17, while SYK trades at $302.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SYK's P/E ratio is 34.11. In terms of profitability, INGN's ROE is -0.13%, compared to SYK's ROE of +0.15%. Regarding short-term risk, INGN is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SYK's competition here
INGN vs MDT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, MDT has a market cap of 100.2B. Regarding current trading prices, INGN is priced at $6.17, while MDT trades at $80.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas MDT's P/E ratio is 21.80. In terms of profitability, INGN's ROE is -0.13%, compared to MDT's ROE of +0.10%. Regarding short-term risk, INGN is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check MDT's competition here
INGN vs BSX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BSX has a market cap of 70.9B. Regarding current trading prices, INGN is priced at $6.17, while BSX trades at $48.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BSX's P/E ratio is 19.96. In terms of profitability, INGN's ROE is -0.13%, compared to BSX's ROE of +0.15%. Regarding short-term risk, INGN is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check BSX's competition here
INGN vs BRKRP Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BRKRP has a market cap of 70.4B. Regarding current trading prices, INGN is priced at $6.17, while BRKRP trades at $462.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BRKRP's P/E ratio is N/A. In terms of profitability, INGN's ROE is -0.13%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, INGN is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check BRKRP's competition here
INGN vs EW Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, EW has a market cap of 49.5B. Regarding current trading prices, INGN is priced at $6.17, while EW trades at $87.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas EW's P/E ratio is 46.51. In terms of profitability, INGN's ROE is -0.13%, compared to EW's ROE of +0.11%. Regarding short-term risk, INGN is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check EW's competition here
INGN vs DXCM Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, DXCM has a market cap of 28.1B. Regarding current trading prices, INGN is priced at $6.17, while DXCM trades at $74.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas DXCM's P/E ratio is 31.23. In terms of profitability, INGN's ROE is -0.13%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, INGN is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check DXCM's competition here
INGN vs RMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, RMD has a market cap of 27.1B. Regarding current trading prices, INGN is priced at $6.17, while RMD trades at $191.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas RMD's P/E ratio is 17.98. In terms of profitability, INGN's ROE is -0.13%, compared to RMD's ROE of +0.24%. Regarding short-term risk, INGN is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check RMD's competition here
INGN vs PHG Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PHG has a market cap of 24.1B. Regarding current trading prices, INGN is priced at $6.17, while PHG trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PHG's P/E ratio is 21.86. In terms of profitability, INGN's ROE is -0.13%, compared to PHG's ROE of +0.09%. Regarding short-term risk, INGN is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check PHG's competition here
INGN vs STE Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, STE has a market cap of 20.6B. Regarding current trading prices, INGN is priced at $6.17, while STE trades at $215.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas STE's P/E ratio is 26.52. In terms of profitability, INGN's ROE is -0.13%, compared to STE's ROE of +0.11%. Regarding short-term risk, INGN is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check STE's competition here
INGN vs ABMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, INGN is priced at $6.17, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ABMD's P/E ratio is 65.36. In terms of profitability, INGN's ROE is -0.13%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, INGN is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ABMD's competition here
INGN vs ZBH Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ZBH has a market cap of 16.4B. Regarding current trading prices, INGN is priced at $6.17, while ZBH trades at $86.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ZBH's P/E ratio is 22.02. In terms of profitability, INGN's ROE is -0.13%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, INGN is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ZBH's competition here
INGN vs SNN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, INGN is priced at $6.17, while SNN trades at $30.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SNN's P/E ratio is 20.93. In terms of profitability, INGN's ROE is -0.13%, compared to SNN's ROE of +0.12%. Regarding short-term risk, INGN is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check SNN's competition here
INGN vs SWAV Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, INGN is priced at $6.17, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SWAV's P/E ratio is 78.76. In terms of profitability, INGN's ROE is -0.13%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, INGN is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SWAV's competition here
INGN vs PEN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, INGN is priced at $6.17, while PEN trades at $321.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PEN's P/E ratio is 73.76. In terms of profitability, INGN's ROE is -0.13%, compared to PEN's ROE of +0.12%. Regarding short-term risk, INGN is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check PEN's competition here
INGN vs ALGN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ALGN has a market cap of 11.6B. Regarding current trading prices, INGN is priced at $6.17, while ALGN trades at $166.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ALGN's P/E ratio is 27.22. In terms of profitability, INGN's ROE is -0.13%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, INGN is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ALGN's competition here
INGN vs GMED Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, INGN is priced at $6.17, while GMED trades at $79.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas GMED's P/E ratio is 18.21. In terms of profitability, INGN's ROE is -0.13%, compared to GMED's ROE of +0.13%. Regarding short-term risk, INGN is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check GMED's competition here
INGN vs PODD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PODD has a market cap of 9.9B. Regarding current trading prices, INGN is priced at $6.17, while PODD trades at $150.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PODD's P/E ratio is 33.48. In terms of profitability, INGN's ROE is -0.13%, compared to PODD's ROE of +0.21%. Regarding short-term risk, INGN is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check PODD's competition here
INGN vs BRKR Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BRKR has a market cap of 9.5B. Regarding current trading prices, INGN is priced at $6.17, while BRKR trades at $62.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BRKR's P/E ratio is -261.25. In terms of profitability, INGN's ROE is -0.13%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, INGN is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check BRKR's competition here
INGN vs MASI Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, INGN is priced at $6.17, while MASI trades at $178.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas MASI's P/E ratio is 44.36. In terms of profitability, INGN's ROE is -0.13%, compared to MASI's ROE of +0.09%. Regarding short-term risk, INGN is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check MASI's competition here
INGN vs BIO-B Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, INGN is priced at $6.17, while BIO-B trades at $304.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BIO-B's P/E ratio is 50.64. In terms of profitability, INGN's ROE is -0.13%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, INGN is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check BIO-B's competition here
INGN vs BIO Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BIO has a market cap of 8.2B. Regarding current trading prices, INGN is priced at $6.17, while BIO trades at $309.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BIO's P/E ratio is 50.60. In terms of profitability, INGN's ROE is -0.13%, compared to BIO's ROE of +0.02%. Regarding short-term risk, INGN is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check BIO's competition here
INGN vs GKOS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, GKOS has a market cap of 6.7B. Regarding current trading prices, INGN is priced at $6.17, while GKOS trades at $116.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas GKOS's P/E ratio is -34.45. In terms of profitability, INGN's ROE is -0.13%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, INGN is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check GKOS's competition here
INGN vs NARI Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, INGN is priced at $6.17, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas NARI's P/E ratio is -59.24. In terms of profitability, INGN's ROE is -0.13%, compared to NARI's ROE of -0.00%. Regarding short-term risk, INGN is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check NARI's competition here
INGN vs LIVN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, LIVN has a market cap of 3.9B. Regarding current trading prices, INGN is priced at $6.17, while LIVN trades at $72.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas LIVN's P/E ratio is 36.39. In terms of profitability, INGN's ROE is -0.13%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, INGN is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check LIVN's competition here
INGN vs AXNX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, INGN is priced at $6.17, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas AXNX's P/E ratio is -709.80. In terms of profitability, INGN's ROE is -0.13%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, INGN is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check AXNX's competition here
INGN vs IRTC Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, IRTC has a market cap of 3.4B. Regarding current trading prices, INGN is priced at $6.17, while IRTC trades at $105.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas IRTC's P/E ratio is -123.01. In terms of profitability, INGN's ROE is -0.13%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, INGN is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check IRTC's competition here
INGN vs ITGR Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, INGN is priced at $6.17, while ITGR trades at $92.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ITGR's P/E ratio is 22.56. In terms of profitability, INGN's ROE is -0.13%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, INGN is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ITGR's competition here
INGN vs TMDX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, INGN is priced at $6.17, while TMDX trades at $71.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas TMDX's P/E ratio is 15.95. In terms of profitability, INGN's ROE is -0.13%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, INGN is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check TMDX's competition here
INGN vs AXGN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, INGN is priced at $6.17, while AXGN trades at $41.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas AXGN's P/E ratio is -63.48. In terms of profitability, INGN's ROE is -0.13%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, INGN is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check AXGN's competition here
INGN vs ESTA Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, INGN is priced at $6.17, while ESTA trades at $74.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ESTA's P/E ratio is -49.26. In terms of profitability, INGN's ROE is -0.13%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, INGN is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ESTA's competition here
INGN vs NUVA Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, INGN is priced at $6.17, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas NUVA's P/E ratio is 75.00. In terms of profitability, INGN's ROE is -0.13%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, INGN is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check NUVA's competition here
INGN vs UFPT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, INGN is priced at $6.17, while UFPT trades at $224.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas UFPT's P/E ratio is 24.84. In terms of profitability, INGN's ROE is -0.13%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, INGN is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check UFPT's competition here
INGN vs PRCT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, INGN is priced at $6.17, while PRCT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PRCT's P/E ratio is -14.39. In terms of profitability, INGN's ROE is -0.13%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, INGN is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check PRCT's competition here
INGN vs AHCO Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, INGN is priced at $6.17, while AHCO trades at $9.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas AHCO's P/E ratio is -16.47. In terms of profitability, INGN's ROE is -0.13%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, INGN is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check AHCO's competition here
INGN vs HSKA Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, INGN is priced at $6.17, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas HSKA's P/E ratio is -62.49. In terms of profitability, INGN's ROE is -0.13%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, INGN is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check HSKA's competition here
INGN vs IART Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, INGN is priced at $6.17, while IART trades at $16.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas IART's P/E ratio is -2.49. In terms of profitability, INGN's ROE is -0.13%, compared to IART's ROE of -0.48%. Regarding short-term risk, INGN is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check IART's competition here
INGN vs ENOV Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, INGN is priced at $6.17, while ENOV trades at $22.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ENOV's P/E ratio is -1.08. In terms of profitability, INGN's ROE is -0.13%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, INGN is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ENOV's competition here
INGN vs TNDM Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, INGN is priced at $6.17, while TNDM trades at $18.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas TNDM's P/E ratio is -13.16. In terms of profitability, INGN's ROE is -0.13%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, INGN is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check TNDM's competition here
INGN vs ATEC Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, INGN is priced at $6.17, while ATEC trades at $7.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ATEC's P/E ratio is -9.25. In terms of profitability, INGN's ROE is -0.13%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, INGN is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ATEC's competition here
INGN vs AVNS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, INGN is priced at $6.17, while AVNS trades at $25.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas AVNS's P/E ratio is -15.60. In terms of profitability, INGN's ROE is -0.13%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, INGN is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check AVNS's competition here
INGN vs INSP Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, INGN is priced at $6.17, while INSP trades at $42.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas INSP's P/E ratio is 9.20. In terms of profitability, INGN's ROE is -0.13%, compared to INSP's ROE of +0.18%. Regarding short-term risk, INGN is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check INSP's competition here
INGN vs IRMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, INGN is priced at $6.17, while IRMD trades at $93.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas IRMD's P/E ratio is 49.79. In terms of profitability, INGN's ROE is -0.13%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, INGN is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check IRMD's competition here
INGN vs BFLY Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BFLY has a market cap of 1.1B. Regarding current trading prices, INGN is priced at $6.17, while BFLY trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BFLY's P/E ratio is -14.65. In terms of profitability, INGN's ROE is -0.13%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, INGN is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check BFLY's competition here
INGN vs SILK Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, INGN is priced at $6.17, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SILK's P/E ratio is -18.96. In terms of profitability, INGN's ROE is -0.13%, compared to SILK's ROE of -0.35%. Regarding short-term risk, INGN is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SILK's competition here
INGN vs FNA Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, INGN is priced at $6.17, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas FNA's P/E ratio is -19.83. In terms of profitability, INGN's ROE is -0.13%, compared to FNA's ROE of -0.35%. Regarding short-term risk, INGN is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check FNA's competition here
INGN vs AORT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, AORT has a market cap of 999.3M. Regarding current trading prices, INGN is priced at $6.17, while AORT trades at $21.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas AORT's P/E ratio is 82.34. In terms of profitability, INGN's ROE is -0.13%, compared to AORT's ROE of +0.03%. Regarding short-term risk, INGN is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check AORT's competition here
INGN vs CNMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CNMD has a market cap of 996.5M. Regarding current trading prices, INGN is priced at $6.17, while CNMD trades at $34.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CNMD's P/E ratio is 18.70. In terms of profitability, INGN's ROE is -0.13%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, INGN is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check CNMD's competition here
INGN vs SSII Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SSII has a market cap of 862.6M. Regarding current trading prices, INGN is priced at $6.17, while SSII trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SSII's P/E ratio is -86.20. In terms of profitability, INGN's ROE is -0.13%, compared to SSII's ROE of -0.23%. Regarding short-term risk, INGN is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check SSII's competition here
INGN vs INMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, INMD has a market cap of 854.7M. Regarding current trading prices, INGN is priced at $6.17, while INMD trades at $13.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas INMD's P/E ratio is 9.99. In terms of profitability, INGN's ROE is -0.13%, compared to INMD's ROE of +0.13%. Regarding short-term risk, INGN is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check INMD's competition here
INGN vs CSII Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, INGN is priced at $6.17, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CSII's P/E ratio is -20.83. In terms of profitability, INGN's ROE is -0.13%, compared to CSII's ROE of -0.14%. Regarding short-term risk, INGN is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check CSII's competition here
INGN vs LMRI Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, LMRI has a market cap of 746.5M. Regarding current trading prices, INGN is priced at $6.17, while LMRI trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas LMRI's P/E ratio is -19.92. In terms of profitability, INGN's ROE is -0.13%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, INGN is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check LMRI's competition here
INGN vs CRY Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, INGN is priced at $6.17, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CRY's P/E ratio is 425.71. In terms of profitability, INGN's ROE is -0.13%, compared to CRY's ROE of +0.03%. Regarding short-term risk, INGN is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check CRY's competition here
INGN vs CBLL Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CBLL has a market cap of 651.9M. Regarding current trading prices, INGN is priced at $6.17, while CBLL trades at $17.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CBLL's P/E ratio is -10.60. In terms of profitability, INGN's ROE is -0.13%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, INGN is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check CBLL's competition here
INGN vs SIBN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SIBN has a market cap of 617.3M. Regarding current trading prices, INGN is priced at $6.17, while SIBN trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SIBN's P/E ratio is -35.69. In terms of profitability, INGN's ROE is -0.13%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, INGN is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SIBN's competition here
INGN vs SRDX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, INGN is priced at $6.17, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SRDX's P/E ratio is -34.66. In terms of profitability, INGN's ROE is -0.13%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, INGN is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SRDX's competition here
INGN vs APEN Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, INGN is priced at $6.17, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas APEN's P/E ratio is -9.43. In terms of profitability, INGN's ROE is -0.13%, compared to APEN's ROE of -0.85%. Regarding short-term risk, INGN is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check APEN's competition here
INGN vs BVS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BVS has a market cap of 579.2M. Regarding current trading prices, INGN is priced at $6.17, while BVS trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BVS's P/E ratio is 20.85. In terms of profitability, INGN's ROE is -0.13%, compared to BVS's ROE of +0.16%. Regarding short-term risk, INGN is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check BVS's competition here
INGN vs BWAY Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BWAY has a market cap of 550.7M. Regarding current trading prices, INGN is priced at $6.17, while BWAY trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BWAY's P/E ratio is 63.82. In terms of profitability, INGN's ROE is -0.13%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, INGN is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check BWAY's competition here
INGN vs TCMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, TCMD has a market cap of 549.7M. Regarding current trading prices, INGN is priced at $6.17, while TCMD trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas TCMD's P/E ratio is 28.01. In terms of profitability, INGN's ROE is -0.13%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, INGN is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check TCMD's competition here
INGN vs NPCE Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, NPCE has a market cap of 541.4M. Regarding current trading prices, INGN is priced at $6.17, while NPCE trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas NPCE's P/E ratio is -24.43. In terms of profitability, INGN's ROE is -0.13%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, INGN is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check NPCE's competition here
INGN vs ZIMV Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, INGN is priced at $6.17, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, INGN's ROE is -0.13%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, INGN is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ZIMV's competition here
INGN vs CERS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CERS has a market cap of 533M. Regarding current trading prices, INGN is priced at $6.17, while CERS trades at $2.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CERS's P/E ratio is -53.20. In terms of profitability, INGN's ROE is -0.13%, compared to CERS's ROE of -0.15%. Regarding short-term risk, INGN is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check CERS's competition here
INGN vs CTKB Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CTKB has a market cap of 523M. Regarding current trading prices, INGN is priced at $6.17, while CTKB trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CTKB's P/E ratio is -6.98. In terms of profitability, INGN's ROE is -0.13%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, INGN is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check CTKB's competition here
INGN vs PACB Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PACB has a market cap of 490.8M. Regarding current trading prices, INGN is priced at $6.17, while PACB trades at $1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PACB's P/E ratio is -3.85. In terms of profitability, INGN's ROE is -0.13%, compared to PACB's ROE of -4.88%. Regarding short-term risk, INGN is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check PACB's competition here
INGN vs PMI Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PMI has a market cap of 476.9M. Regarding current trading prices, INGN is priced at $6.17, while PMI trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PMI's P/E ratio is -0.40. In terms of profitability, INGN's ROE is -0.13%, compared to PMI's ROE of +4.99%. Regarding short-term risk, INGN is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check PMI's competition here
INGN vs LAB Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, LAB has a market cap of 445M. Regarding current trading prices, INGN is priced at $6.17, while LAB trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas LAB's P/E ratio is -8.77. In terms of profitability, INGN's ROE is -0.13%, compared to LAB's ROE of -0.21%. Regarding short-term risk, INGN is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check LAB's competition here
INGN vs KIDS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, KIDS has a market cap of 434.6M. Regarding current trading prices, INGN is priced at $6.17, while KIDS trades at $17.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas KIDS's P/E ratio is -10.07. In terms of profitability, INGN's ROE is -0.13%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, INGN is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check KIDS's competition here
INGN vs VREX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, VREX has a market cap of 427.7M. Regarding current trading prices, INGN is priced at $6.17, while VREX trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas VREX's P/E ratio is -5.08. In terms of profitability, INGN's ROE is -0.13%, compared to VREX's ROE of -0.18%. Regarding short-term risk, INGN is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check VREX's competition here
INGN vs CLPT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CLPT has a market cap of 398.9M. Regarding current trading prices, INGN is priced at $6.17, while CLPT trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CLPT's P/E ratio is -13.30. In terms of profitability, INGN's ROE is -0.13%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, INGN is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check CLPT's competition here
INGN vs OFIX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, OFIX has a market cap of 392.9M. Regarding current trading prices, INGN is priced at $6.17, while OFIX trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas OFIX's P/E ratio is -6.48. In terms of profitability, INGN's ROE is -0.13%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, INGN is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check OFIX's competition here
INGN vs VMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, VMD has a market cap of 366.5M. Regarding current trading prices, INGN is priced at $6.17, while VMD trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas VMD's P/E ratio is 25.84. In terms of profitability, INGN's ROE is -0.13%, compared to VMD's ROE of +0.11%. Regarding short-term risk, INGN is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check VMD's competition here
INGN vs DCTH Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, DCTH has a market cap of 356.6M. Regarding current trading prices, INGN is priced at $6.17, while DCTH trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas DCTH's P/E ratio is 1033.00. In terms of profitability, INGN's ROE is -0.13%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, INGN is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check DCTH's competition here
INGN vs AVR Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, AVR has a market cap of 329.3M. Regarding current trading prices, INGN is priced at $6.17, while AVR trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas AVR's P/E ratio is -4.03. In terms of profitability, INGN's ROE is -0.13%, compared to AVR's ROE of -1.24%. Regarding short-term risk, INGN is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check AVR's competition here
INGN vs MASS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, MASS has a market cap of 327.5M. Regarding current trading prices, INGN is priced at $6.17, while MASS trades at $8.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas MASS's P/E ratio is -8.93. In terms of profitability, INGN's ROE is -0.13%, compared to MASS's ROE of -0.26%. Regarding short-term risk, INGN is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check MASS's competition here
INGN vs SMLR Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, INGN is priced at $6.17, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SMLR's P/E ratio is 3.92. In terms of profitability, INGN's ROE is -0.13%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, INGN is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SMLR's competition here
INGN vs ELMD Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ELMD has a market cap of 296.1M. Regarding current trading prices, INGN is priced at $6.17, while ELMD trades at $36.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ELMD's P/E ratio is 30.56. In terms of profitability, INGN's ROE is -0.13%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, INGN is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ELMD's competition here
INGN vs SENS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SENS has a market cap of 280.7M. Regarding current trading prices, INGN is priced at $6.17, while SENS trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SENS's P/E ratio is -3.41. In terms of profitability, INGN's ROE is -0.13%, compared to SENS's ROE of -1.30%. Regarding short-term risk, INGN is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SENS's competition here
INGN vs CATX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CATX has a market cap of 273.5M. Regarding current trading prices, INGN is priced at $6.17, while CATX trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CATX's P/E ratio is -2.51. In terms of profitability, INGN's ROE is -0.13%, compared to CATX's ROE of -0.42%. Regarding short-term risk, INGN is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check CATX's competition here
INGN vs MGRM Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, INGN is priced at $6.17, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas MGRM's P/E ratio is -11.11. In terms of profitability, INGN's ROE is -0.13%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, INGN is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check MGRM's competition here
INGN vs SGHT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SGHT has a market cap of 236.1M. Regarding current trading prices, INGN is priced at $6.17, while SGHT trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SGHT's P/E ratio is -6.20. In terms of profitability, INGN's ROE is -0.13%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, INGN is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check SGHT's competition here
INGN vs NVRO Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, INGN is priced at $6.17, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas NVRO's P/E ratio is -1.91. In terms of profitability, INGN's ROE is -0.13%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, INGN is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check NVRO's competition here
INGN vs TMCI Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, TMCI has a market cap of 220.6M. Regarding current trading prices, INGN is priced at $6.17, while TMCI trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas TMCI's P/E ratio is -3.54. In terms of profitability, INGN's ROE is -0.13%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, INGN is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check TMCI's competition here
INGN vs EYES Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, INGN is priced at $6.17, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas EYES's P/E ratio is N/A. In terms of profitability, INGN's ROE is -0.13%, compared to EYES's ROE of -2.64%. Regarding short-term risk, INGN is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check EYES's competition here
INGN vs RXST Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, RXST has a market cap of 198.3M. Regarding current trading prices, INGN is priced at $6.17, while RXST trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas RXST's P/E ratio is -4.24. In terms of profitability, INGN's ROE is -0.13%, compared to RXST's ROE of -0.17%. Regarding short-term risk, INGN is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check RXST's competition here
INGN vs PROF Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, PROF has a market cap of 198.2M. Regarding current trading prices, INGN is priced at $6.17, while PROF trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas PROF's P/E ratio is -5.28. In terms of profitability, INGN's ROE is -0.13%, compared to PROF's ROE of -0.71%. Regarding short-term risk, INGN is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check PROF's competition here
INGN vs ANIK Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, ANIK has a market cap of 191.7M. Regarding current trading prices, INGN is priced at $6.17, while ANIK trades at $14.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas ANIK's P/E ratio is -18.24. In terms of profitability, INGN's ROE is -0.13%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, INGN is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check ANIK's competition here
INGN vs BSGM Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, INGN is priced at $6.17, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas BSGM's P/E ratio is -5.81. In terms of profitability, INGN's ROE is -0.13%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, INGN is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check BSGM's competition here
INGN vs MDGS Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, INGN is priced at $6.17, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas MDGS's P/E ratio is -0.27. In terms of profitability, INGN's ROE is -0.13%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, INGN is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check MDGS's competition here
INGN vs EDAP Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, INGN is priced at $6.17, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas EDAP's P/E ratio is -5.80. In terms of profitability, INGN's ROE is -0.13%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, INGN is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check EDAP's competition here
INGN vs QTRX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, QTRX has a market cap of 166.3M. Regarding current trading prices, INGN is priced at $6.17, while QTRX trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas QTRX's P/E ratio is -1.50. In terms of profitability, INGN's ROE is -0.13%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, INGN is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check QTRX's competition here
INGN vs QIPT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, INGN is priced at $6.17, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas QIPT's P/E ratio is -15.87. In terms of profitability, INGN's ROE is -0.13%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, INGN is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check QIPT's competition here
INGN vs APYX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, APYX has a market cap of 158.7M. Regarding current trading prices, INGN is priced at $6.17, while APYX trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas APYX's P/E ratio is -17.23. In terms of profitability, INGN's ROE is -0.13%, compared to APYX's ROE of -0.91%. Regarding short-term risk, INGN is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check APYX's competition here
INGN vs CVRX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, CVRX has a market cap of 143M. Regarding current trading prices, INGN is priced at $6.17, while CVRX trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas CVRX's P/E ratio is -2.68. In terms of profitability, INGN's ROE is -0.13%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, INGN is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for INGN.Check CVRX's competition here
INGN vs SNWV Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, SNWV has a market cap of 134.1M. Regarding current trading prices, INGN is priced at $6.17, while SNWV trades at $15.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas SNWV's P/E ratio is 16.25. In terms of profitability, INGN's ROE is -0.13%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, INGN is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check SNWV's competition here
INGN vs NNOX Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, NNOX has a market cap of 130.1M. Regarding current trading prices, INGN is priced at $6.17, while NNOX trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas NNOX's P/E ratio is -1.61. In terms of profitability, INGN's ROE is -0.13%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, INGN is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check NNOX's competition here
INGN vs MXCT Comparison June 2026
INGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INGN stands at 161.9M. In comparison, MXCT has a market cap of 128.5M. Regarding current trading prices, INGN is priced at $6.17, while MXCT trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INGN currently has a P/E ratio of -6.57, whereas MXCT's P/E ratio is -3.33. In terms of profitability, INGN's ROE is -0.13%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, INGN is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for INGN.Check MXCT's competition here